Hyderabad-based Biological E joins hands with J&J for Covid-19 vaccine

Biological E is going to use its manufacturing infrastructure to support J&J's global commitment to global access for its Covid-19 vaccine
Hyderabad-based pharma company  Biological E Limited (BE) has entered into an agreement with Janssen Pharmaceuticals for the development and manufacturing of Covid-19 drugs as well as Johnson &Johnson's (J&J) Covid-19 vaccine candidate.

 
The vaccine candidate is in phase 1/2a clinical trials.

 
Managing Director of Biological E, Mahima Datla said, "We are very pleased indeed to collaborate with an organisation like Johnson & Johnson. Given the magnitude of the Covid-19 pandemic, our ability to mount an effective response will be predicated on the ability to supply the vaccine globally and in significant quantities. This is best achieved through collaboration."

 
Biological E is going to use its manufacturing infrastructure to support J&J's global commitment to global access for its Covid-19 vaccine.

 
Meanwhile, Baylor College of Medicine and Biological E announced a licensing agreement for the development of a safe, effective and affordable Covid-19 vaccine.

 
Datla said that the partnership with Baylor would help accelerate the development of an affordable vaccine, especially for India and other low and middle-income nations.

 


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel